ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1987

Evaluating User Engagement and Real-World Impact of a PMR-Specific Digital Symptom Assessment Tool: A 12-Month Analysis of PainSpot™

Shilpa Venkatachalam1, Erik Stone2, Ian Carroll3, angela Degrassi3, Shelley Fritz4 and David Curtis5, 1Global Healthy Living Foundation, New York, NY, 2Global Healthy Living Foundation, Nyack, NY, 3Global Healthy Living Foundation, Upper Nyack, NY, 4Global Healthy Living Foundation, Kalaheo, HI, 5Global Healthy Living Foundation, Meriden

Meeting: ACR Convergence 2025

Keywords: Back pain, education, patient, pain, Polymyalgia Rheumatica (PMR), shoulder disorders

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1972–1989) Measures & Measurement of Healthcare Quality Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory condition affecting individuals over 50, marked by bilateral shoulder and hip stiffness and pain. Its nonspecific symptoms and overlap with other musculoskeletal disorders often lead to diagnostic delays and misclassification, contributing to avoidable morbidity. Awareness of PMR remains limited, especially outside of rheumatology. Digital tools, such as algorithm-based symptom checkers, offer a scalable approach to identifying PMR-consistent symptom patterns and prompting medical evaluation. To address this gap, the PainSpot™ platform was enhanced with a PMR-specific pathway co-developed by clinicians and patients. This study assessed real-world tool engagement, diagnostic likelihood distribution, and user-reported outcomes.

Methods: PainSpot™ was modified to include a PMR-specific algorithm co-developed by a multi-stakeholder working group including rheumatologists, outcomes researchers, and patients with confirmed PMR diagnoses. Thirteen condition-specific questions were generated and refined through a literature review, clinical input, and patient interviews focusing on pre-diagnosis symptom recall. Between March 1, 2024, and February 28, 2025, user-level engagement data were collected and analyzed to evaluate assessment completion rates, PMR likelihood results, and follow-up survey responses.

Results: Of 94,454 users who completed the PainSpot™ assessment between March 2024 and February 2025, a subset were routed to a potential PMR result based on algorithmic analysis of symptom patterns. Among these, 1,509 users (21.0%) were classified as high likelihood of PMR, 4,353 (60.6%) as medium likelihood, and 4,683 (65.2%) as low likelihood. These stratifications were derived from a weighted question algorithm developed through clinician and patient input. Average engagement time across users was 2 minutes and 19 seconds, indicating sustained interaction with the digital interface. Follow-up surveys were administered to users who completed the assessment. Among 111 respondents, 89.2% (n=99) reported discussing their results with a healthcare provider, suggesting potential influence on care-seeking behavior. Additionally, 193 assessment completers (across all diagnostic pathways, not limited to PMR) responded to a separate follow-up question regarding the accuracy of the tool’s output; 82.4% (n=159) indicated that the result they received aligned with their symptom experience or was subsequently confirmed.

Conclusion: The PMR-specific pathway within PainSpot™ demonstrated high engagement meaningful stratification of diagnostic likelihood, and strong perceived utility based on user-reported outcomes.. While only a subset of users confirmed seeking medical follow-up, a larger proportion—over 80% of survey respondents—indicated that the tool’s output aligned with their symptom experience. These findings support the utility of patient-informed, algorithm-based tools in recognizing symptom patterns consistent with PMR. This work aligns with a four-year CDC-funded initiative aimed at improving national awareness, education, and diagnostic strategies for PMR.

Supporting image 1Table 1: PainSpot (TM) PMR Pathway User Engagement Overview

Supporting image 2Figure 1: PMR Likelihood Stratification Among PainSpot Users


Disclosures: S. Venkatachalam: None; E. Stone: None; I. Carroll: None; a. Degrassi: None; S. Fritz: None; D. Curtis: None.

To cite this abstract in AMA style:

Venkatachalam S, Stone E, Carroll I, Degrassi a, Fritz S, Curtis D. Evaluating User Engagement and Real-World Impact of a PMR-Specific Digital Symptom Assessment Tool: A 12-Month Analysis of PainSpot™ [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/evaluating-user-engagement-and-real-world-impact-of-a-pmr-specific-digital-symptom-assessment-tool-a-12-month-analysis-of-painspot/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-user-engagement-and-real-world-impact-of-a-pmr-specific-digital-symptom-assessment-tool-a-12-month-analysis-of-painspot/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology